|
|
|
| Diagnostic role of microRNA-125b for hepatocellular carcinoma |
| Feng Li a , Quan-Wa Bao b , Liu-Yi-Qi Jiang b , Qi-Lin Huang a , Xu Zhang a , Ju-Xiang Chen a , ∗ |
a Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, China
b State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, 2005 Songhu Road, Shanghai 200433, China
∗ Corresponding author.
E-mail address: juxiangchen@smmu.edu.cn (J.-X. Chen). |
|
|
|
|
Abstract It is estimated that there was 841000 new cases of liver cancer and 782000 associated deaths worldwide in 2018, ranking as the sixth most common cancer and the fourth leading cause of cancer-related deaths [1] . With approximately 90% of total cases, hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer, and is a major public global health challenge at present [1] . The majority of HCC patients are usually at advanced stages when diagnosed, which misses the optimal treatment and prognosis is poor. Alpha-fetoprotein (AFP) is the most widely applied diagnostic serum biomarker to detect HCC at present; however, the diagnostic accuracy of AFP is unsatisfactory, with sensitivity of 53% and specificity of 90% for early stage HCC [2] . Recently, plenty of studies reported that microRNA-125b (miR-125b) might function as potential diagnostic biomarker in HCC [3–8] . miR-125 family, consisting of miR-125a, miR-125b-1, and miR-125b-2, is closely associated with differentiation, proliferation, invasion, and metastasis of cancer cells. However, the diagnostic accuracy of miR-125b remains inconsistent.
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
